In the latest trading session, 49.84 million Pasithea Therapeutics Corp (NASDAQ:KTTA) shares changed hands as the company’s beta touched 0.65. With the company’s most recent per share price at $3.17 changing hands around $1.09 or 52.40% at last look, the market valuation stands at $4.01M. KTTA’s current price is a discount, trading about -191.8% off its 52-week high of $9.25. The share price had its 52-week low at $2.03, which suggests the last value was 35.96% up since then. When we look at Pasithea Therapeutics Corp’s average trading volume, we note the 10-day average is 35790.0 shares, with the 3-month average coming to 45.34K.

Pasithea Therapeutics Corp (NASDAQ:KTTA) trade information

Instantly KTTA is in green as seen in intraday trades today. With action 27.82%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 0.63%, with the 5-day performance at 27.82% in the green. However, in the 30-day time frame, Pasithea Therapeutics Corp (NASDAQ:KTTA) is 1.60% up. Looking at the short shares, we see there were 11581.0 shares sold at short interest cover period of 0.32 days.

KTTA Dividends

Pasithea Therapeutics Corp is expected to release its next quarterly earnings report in March.

Pasithea Therapeutics Corp (NASDAQ:KTTA)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 23.12% of Pasithea Therapeutics Corp shares while 2.87% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 3.73%.

Among Mutual Funds, the top two as of Nov 30, 2024 were Fidelity Extended Market Index Fund and Fidelity Series Total Market Index Fund. With 2.96 shares estimated at $9455.0 under it, the former controlled 0.23% of total outstanding shares. On the other hand, Fidelity Series Total Market Index Fund held about 0.07% of the shares, roughly 880.0 shares worth around $2807.0.